Comparative Pharmacology
Head-to-head clinical analysis: JANIMINE versus TRIMIPRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANIMINE versus TRIMIPRAMINE MALEATE.
JANIMINE vs TRIMIPRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Inhibits reuptake of norepinephrine and serotonin, with moderate anticholinergic, sedative, and antihistaminergic effects.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
25-150 mg orally once daily at bedtime, starting at 25 mg and titrating up by 25 mg every 3-4 days.
None Documented
None Documented
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Terminal elimination half-life: 22–32 hours (mean 24 hours); in elderly or hepatic impairment, may extend to 40–50 hours requiring dose adjustment.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Renal: ~70% as metabolites (unchanged <5%); fecal: ~30% via biliary excretion.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant